These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16766581)

  • 41. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
    De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
    J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG
    J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status.
    McCann SE; Kulkarni S; Trevisan M; Vito D; Nie J; Edge SB; Muti P; Freudenheim JL
    Breast Cancer Res Treat; 2006 Oct; 99(3):309-11. PubMed ID: 16541305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phyto-oestrogens and breast cancer chemoprevention.
    Limer JL; Speirs V
    Breast Cancer Res; 2004; 6(3):119-27. PubMed ID: 15084232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics.
    McPherson K; Steel CM; Dixon JM
    BMJ; 2000 Sep; 321(7261):624-8. PubMed ID: 10977847
    [No Abstract]   [Full Text] [Related]  

  • 46. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
    Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
    Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Primary prevention of breast cancer in women with an increased risk for breast cancer--a prospective, randomized, double-blind study (NSABP-P1 study)].
    Reichert D; Illiger HJ
    Strahlenther Onkol; 2000 Jan; 176(1):43-4. PubMed ID: 10650836
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevention of breast cancer.
    Carolin KA; Pass HA
    Crit Rev Oncol Hematol; 2000 Mar; 33(3):221-38. PubMed ID: 10789494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Youth and hormone receptors in breast cancer: good or bad news first?
    Stockler M; Beith J
    Lancet; 2000 May; 355(9218):1839-40. PubMed ID: 10866433
    [No Abstract]   [Full Text] [Related]  

  • 50. Aspirin and breast cancer prevention--a link to ER status.
    Tait CR
    Breast Cancer Res; 2004; 6(5):211-2. PubMed ID: 15318927
    [No Abstract]   [Full Text] [Related]  

  • 51. Raloxifene in breast cancer prevention.
    Gennari L; Merlotti D; Paola VD; Nuti R
    Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
    Herbert BS; Sanders BG; Kline K
    Nutr Cancer; 1999; 34(2):121-32. PubMed ID: 10578478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
    Decensi A; Omodei U; Robertson C; Bonanni B; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Mora S; Sandri MT; Cazzaniga M; Franchi M; Pecorelli S
    Circulation; 2002 Sep; 106(10):1224-8. PubMed ID: 12208797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
    Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
    Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen, raloxifene, and the prevention of breast cancer.
    Jordan VC; Morrow M
    Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
    [No Abstract]   [Full Text] [Related]  

  • 56. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract]   [Full Text] [Related]  

  • 57. Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
    Higa GM
    Expert Opin Pharmacother; 2001 Jun; 2(6):987-95. PubMed ID: 11585014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Researchers probe targeted agents' clinical potential for cancer prevention.
    Hampton T
    JAMA; 2010 Jan; 303(2):115-6. PubMed ID: 20068198
    [No Abstract]   [Full Text] [Related]  

  • 60. Specific keynote: chemoprevention of ovarian cancer: the journey begins.
    Ozols RF; Daly MB; Klein-Szanto A; Hamilton TC; Bast RC; Brewer MA
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S59-66; discussion S67-70. PubMed ID: 12586088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.